Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer.
Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer.
复制标题
DOI：
10.3390/cancers3010603
复制
发表时间：
2011-02-10
期刊：
影响因子：
5.2
通讯作者：
Griffith TS
中科院分区：
文献类型：
--
作者：
Norian LA;James BR;Griffith TS
许多生物学方法正在研究作为抗癌疗法，试图诱导肿瘤消退，同时避免与标准化疗或放疗相关的毒副作用。其中，肿瘤坏死因子相关凋亡诱导配体（TRAIL）由于其诱导癌细胞凋亡的优先能力和其最小的毒性，在临床前和早期临床试验中显示出特别的前景。使用TRAIL的一个限制是许多肿瘤类型显示出对TRAIL诱导的细胞凋亡的固有抗性。为了解决这个问题，研究人员已经探索了许多策略来优化TRAIL的递送，并通过与其他抗癌药物共同给药来提高其疗效。在这篇综述中，我们将集中在TRAIL为基础的基因治疗方法治疗恶性肿瘤。我们将讨论用于TRAIL基因治疗的主要病毒载体，以及目前正在尝试提高TRAIL作为抗癌治疗剂的疗效的策略。
Numerous biologic approaches are being investigated as anti-cancer therapies in an attempt to induce tumor regression while circumventing the toxic side effects associated with standard chemo- or radiotherapies. Among these, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has shown particular promise in pre-clinical and early clinical trials, due to its preferential ability to induce apoptotic cell death in cancer cells and its minimal toxicity. One limitation of TRAIL use is the fact that many tumor types display an inherent resistance to TRAIL-induced apoptosis. To circumvent this problem, researchers have explored a number of strategies to optimize TRAIL delivery and to improve its efficacy via co-administration with other anti-cancer agents. In this review, we will focus on TRAIL-based gene therapy approaches for the treatment of malignancies. We will discuss the main viral vectors that are being used for TRAIL gene therapy and the strategies that are currently being attempted to improve the efficacy of TRAIL as an anti-cancer therapeutic.